Crinetics Pharmaceuticals, Inc.
CRNX
Helyezés a részvények között
#2243
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Részvényárfolyam
$84.95
Utolsó szinkronizálás: 2026-09-01
Piaci kapitalizáció
$9.00B
Változás (1 nap)
0.00%
Változás (1 év)
100.12%
Ország
US
Kereskedés Crinetics Pharmaceuticals, Inc. (CRNX)
Kategória
Healthcare
EPS Crinetics Pharmaceuticals, Inc. (CRNX) részvényre
EPS June 2026 dátummal, TTM: $-5.05
Crinetics Pharmaceuticals, Inc. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi EPS mutatója (TTM) $-5.05. 2023 végén a vállalat EPS mutatója $-3.69 volt, növekedés a 2022 év EPS értékéhez, amely $-3.15 volt.
Crinetics Pharmaceuticals, Inc. EPS története 2016 és 2026 között
EPS minden év végén
| Év | EPS | Változtassa meg |
|---|---|---|
| 2026 (TTM) | $-5.05 | 36.86% |
| 2024 | $-3.69 | 0.00% |
| 2023 | $-3.69 | 17.14% |
| 2022 | $-3.15 | 12.50% |
| 2021 | $-2.80 | 15.70% |
| 2020 | $-2.42 | 18.05% |
| 2019 | $-2.05 | -8.07% |
| 2018 | $-2.23 | 237.88% |
| 2017 | $-0.66 | 53.49% |
| 2016 | $-0.43 | 0.00% |
EPS hasonló cégek vagy versenytársak esetén
| Vállalat | EPS | EPS különbség | Ország |
|---|---|---|---|
| $17.32 | -442.97% |
US
|
|
| $-7.98 | 58.02% |
US
|
|
| $-5.29 | 4.75% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -649.31% |
NL
|
